Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
The Liberal Democratic Party (LDP) and Japan Innovation Party (Nippon Ishin) on March 19 resumed their bilateral talks on social security reform after a three-month hiatus, with Ishin proposing the introduction of a so-called macroeconomic indexing mechanism for healthcare spending.…
To read the full story
Related Article
- LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
- LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
- LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- LDP, Ishin Call for Proper Valuation in CEA Scheme at Reform Talks
April 3, 2026
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
REGULATORY
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
- Share of Negative-Margin WPPs Rises to 6.9%, Wholesalers Cite Communication Gap
July 24, 2026
- MHLW Unveils Preventive Healthcare Plan Focused on Dementia, Other Areas
July 24, 2026
- MHLW Eyes Limited Charge Exemptions for OTC-Like Topical Drugs
July 24, 2026
- MHLW Panel Voices Disappointment over Efluelda Launch Delay
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…